Literature DB >> 21321144

In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Maria Souli1, Irene Galani, Stefanos Boukovalas, Michael George Gourgoulis, Zoi Chryssouli, Kyriaki Kanellakopoulou, Theofano Panagea, Helen Giamarellou.   

Abstract

Using time-kill methodology, we investigated the interactions of fosfomycin with meropenem or colistin or gentamicin against 17 genetically distinct Klebsiella pneumoniae clinical isolates carrying blaKPC-2. Synergy was observed with meropenem or colistin against 64.7 and 11.8% of tested isolates, while the combination with gentamicin resulted in indifference. All studied combinations showed improved bactericidal activity, compared to fosfomycin alone and prevented the development of fosfomycin resistance in 69.2, 53.8, and 81.8% of susceptible isolates, respectively.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321144      PMCID： PMC3088223          DOI： 10.1128/AAC.01086-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Authors:  Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

2.  In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.

Authors:  Thidarat Netikul; Amornrut Leelaporn; Amorn Leelarasmee; Pattarachai Kiratisin
Journal:  Int J Antimicrob Agents       Date:  2010-03-01       Impact factor: 5.283

3.  Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.

Authors:  Matthew J Ellington; David M Livermore; Tyrone L Pitt; Lucinda M C Hall; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2006-08-05       Impact factor: 5.790

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis.

Authors:  Bettina Pfausler; Heinrich Spiss; Peter Dittrich; Markus Zeitlinger; Erich Schmutzhard; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

6.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Authors:  Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

7.  An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.

Authors:  Maria Souli; Irene Galani; Anastasia Antoniadou; Evangelos Papadomichelakis; Garyphallia Poulakou; Theofano Panagea; Sofia Vourli; Loukia Zerva; Apostolos Armaganidis; Kyriaki Kanellakopoulou; Helen Giamarellou
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 8.  Pharmacokinetic and pharmacodynamic properties of meropenem.

Authors:  David P Nicolau
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

9.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

10.  Use of boronic acid disk tests to detect extended- spectrum beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae.

Authors:  Athanassios Tsakris; Aggeliki Poulou; Katerina Themeli-Digalaki; Evangelia Voulgari; Theodore Pittaras; Danai Sofianou; Spyros Pournaras; Dimitra Petropoulou
Journal:  J Clin Microbiol       Date:  2009-09-02       Impact factor: 5.948
View more
  30 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Authors:  Miao Zhao; Zackery P Bulman; Justin R Lenhard; Michael J Satlin; Barry N Kreiswirth; Thomas J Walsh; Amanda Marrocco; Phillip J Bergen; Roger L Nation; Jian Li; Jing Zhang; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 3.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

4.  Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Authors:  T Tängdén; R A Hickman; P Forsberg; P Lagerbäck; C G Giske; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

5.  Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jonathan S Gall; Jurgen B Bulitta; Visanu Thamlikitkul; Cornelia B Landersdorfer; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-09-20       Impact factor: 5.283

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 7.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

8.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.